Shanghai Junshi Biosciences Co., Ltd. is a high-risk pharmaceutical company based in China, with a risk rating score of 34.4. Specializing in innovative drug discovery and development on a global scale, Shanghai Junshi aims to create first-in-class drugs through original innovation and co-development. With operations in both China and the USA, the company has a strong focus on ESG principles.